Trial Outcomes & Findings for Little Cigar and Cigarillo Warnings for Youth (NCT NCT06413797)

NCT ID: NCT06413797

Last Updated: 2025-12-24

Results Overview

The average willingness to use score will be measured by the average of the responses to the 2 survey questions scores. Question Scoring is on a scale of 1 to 5, where 1 indicates low willingness to use LCCs, and 5 indicates a willingness to use LCCs score.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

928 participants

Primary outcome timeframe

Day 8

Results posted on

2025-12-24

Participant Flow

Participants were recruited and screened for study eligibility online between 7/18/2024- 11/25/2024 and invited to in the study once they were determined to be eligible.

1,039 potential participants began the baseline survey. Of those, 9 did not consent to participate in the study, and 96 did not complete the baseline questionnaire and were not randomized, and 6 did not meet quality control criteria. 928 participants were enrolled and randomized in the study.

Participant milestones

Participant milestones
Measure
FDA Warnings + Image
Participants will receive FDA-proposed LCC warnings with images
FDA Warnings Text-Only Warnings
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
Participants will receive Surgeon General text-only LCC warnings.
Overall Study
STARTED
310
309
309
Overall Study
COMPLETED
310
309
309
Overall Study
NOT COMPLETED
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Little Cigar and Cigarillo Warnings for Youth

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
FDA Warnings + Image
n=310 Participants
Participants will receive FDA-proposed LCC warnings with images
FDA Warnings Text-Only Warnings
n=309 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=309 Participants
Participants will receive Surgeon General text-only LCC warnings.
Total
n=928 Participants
Total of all reporting groups
Age, Continuous
18.5 years
STANDARD_DEVIATION 1.4 • n=30 Participants
18.4 years
STANDARD_DEVIATION 1.5 • n=30 Participants
18.4 years
STANDARD_DEVIATION 1.5 • n=60 Participants
18.5 years
STANDARD_DEVIATION 1.5 • n=219 Participants
Sex/Gender, Customized
Male
161 Participants
n=30 Participants
138 Participants
n=30 Participants
143 Participants
n=60 Participants
442 Participants
n=219 Participants
Sex/Gender, Customized
Female
146 Participants
n=30 Participants
170 Participants
n=30 Participants
165 Participants
n=60 Participants
481 Participants
n=219 Participants
Sex/Gender, Customized
Unknown
3 Participants
n=30 Participants
1 Participants
n=30 Participants
1 Participants
n=60 Participants
5 Participants
n=219 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
73 Participants
n=30 Participants
68 Participants
n=30 Participants
65 Participants
n=60 Participants
206 Participants
n=219 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
236 Participants
n=30 Participants
240 Participants
n=30 Participants
241 Participants
n=60 Participants
717 Participants
n=219 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=30 Participants
1 Participants
n=30 Participants
3 Participants
n=60 Participants
5 Participants
n=219 Participants
Race (NIH/OMB)
American Indian or Alaska Native
4 Participants
n=30 Participants
7 Participants
n=30 Participants
6 Participants
n=60 Participants
17 Participants
n=219 Participants
Race (NIH/OMB)
Asian
15 Participants
n=30 Participants
13 Participants
n=30 Participants
17 Participants
n=60 Participants
45 Participants
n=219 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
n=30 Participants
1 Participants
n=30 Participants
1 Participants
n=60 Participants
3 Participants
n=219 Participants
Race (NIH/OMB)
Black or African American
49 Participants
n=30 Participants
52 Participants
n=30 Participants
56 Participants
n=60 Participants
157 Participants
n=219 Participants
Race (NIH/OMB)
White
194 Participants
n=30 Participants
192 Participants
n=30 Participants
183 Participants
n=60 Participants
569 Participants
n=219 Participants
Race (NIH/OMB)
More than one race
22 Participants
n=30 Participants
12 Participants
n=30 Participants
19 Participants
n=60 Participants
53 Participants
n=219 Participants
Race (NIH/OMB)
Unknown or Not Reported
25 Participants
n=30 Participants
32 Participants
n=30 Participants
27 Participants
n=60 Participants
84 Participants
n=219 Participants
Region of Enrollment
United States
310 Participants
n=30 Participants
309 Participants
n=30 Participants
309 Participants
n=60 Participants
928 Participants
n=219 Participants

PRIMARY outcome

Timeframe: Day 8

Population: Participants who responded to the measures at the time point of interest, day 8

The average willingness to use score will be measured by the average of the responses to the 2 survey questions scores. Question Scoring is on a scale of 1 to 5, where 1 indicates low willingness to use LCCs, and 5 indicates a willingness to use LCCs score.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=255 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=236 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=250 Participants
Participants will receive FDA-proposed LCC warnings with images.
Willingness to Use Little Cigars Cigarillos (LCCs)
3.08 score on a scale
Standard Deviation 1.39
2.99 score on a scale
Standard Deviation 1.40
2.86 score on a scale
Standard Deviation 1.47

SECONDARY outcome

Timeframe: Day 8

Population: Participants who responded to the measures at the time point of interest, day 8

The number of days in the past 7 days that a participant reported using little cigars, range 0-7. Measured by survey, 1 item.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=256 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=236 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=250 Participants
Participants will receive FDA-proposed LCC warnings with images.
Past 7 Days Little Cigar Use
1.86 number of days
Standard Deviation 2.60
1.88 number of days
Standard Deviation 2.59
1.92 number of days
Standard Deviation 2.62

SECONDARY outcome

Timeframe: Day 8

The number of days in the past 7 days that a participant reported using cigarillos, range 0-7. Measured by survey, 1 item.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=256 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=236 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=249 Participants
Participants will receive FDA-proposed LCC warnings with images.
Past 7 Days Cigarillo Use
1.86 number of days
Standard Deviation 2.41
1.82 number of days
Standard Deviation 2.33
1.93 number of days
Standard Deviation 2.57

SECONDARY outcome

Timeframe: Day 8

Population: Participants who responded to the measures at the time point of interest, day 8

The average susceptibility to little cigar and cigarillo (LCC) use measured with the average of 3 survey item scores. Question scoring is on a scale of 1 to 4, where 1 indicates high susceptibility and 4 indicates low susceptibility to LCCs.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=256 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=236 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=250 Participants
Participants will receive FDA-proposed LCC warnings with images.
Little Cigar and Cigarillos (LCCs) Susceptibility
2.49 score on a scale
Standard Deviation 0.91
2.46 score on a scale
Standard Deviation 0.95
2.33 score on a scale
Standard Deviation 0.97

SECONDARY outcome

Timeframe: Day 2

Population: Participants who responded to the scale at the time point of interest, day 2

The cognitive elaboration score is measured by survey with 1 item. Question scoring is on a scale of 1 to 6, where 1 indicates that the participant has low cognitive elaboration about the health risks of LCCs and 6 indicates that a participant has high cognitive elaboration about smoking LCCs.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=229 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=205 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=218 Participants
Participants will receive FDA-proposed LCC warnings with images.
Cognitive Elaboration About Risk of Little Cigar and Cigarillo Use
3.90 units on a scale
Standard Deviation 1.64
3.91 units on a scale
Standard Deviation 1.60
3.78 units on a scale
Standard Deviation 1.60

SECONDARY outcome

Timeframe: Day 2

Population: Participants who responded to the scale at the time point of interest, day 2

Warning negative affect/worry is measured by survey with 1 item. Question scoring is on a scale of 1 to 5, where 1 indicates low worry due to the warning and 5 indicates high worry due to the warning.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=229 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=205 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=218 Participants
Participants will receive FDA-proposed LCC warnings with images.
Warning Negative Affect/Worry
3.85 units on a scale
Standard Deviation 1.23
3.61 units on a scale
Standard Deviation 1.26
3.79 units on a scale
Standard Deviation 1.16

SECONDARY outcome

Timeframe: Day 8

Population: Participants who responded to the measures at the time point of interest, day 8

Knowledge of LCC harms will be measured by 12 items the survey. Scores can range from 0 to 12 and indicate the number of questions out of 12 about LCC harms that participants answered correctly.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=256 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=236 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=250 Participants
Participants will receive FDA-proposed LCC warnings with images.
Knowledge of Little Cigar and Cigarillo (LCC) Harms
10.12 score on a scale
Standard Deviation 2.46
9.71 score on a scale
Standard Deviation 2.82
10.06 score on a scale
Standard Deviation 2.63

SECONDARY outcome

Timeframe: Day 8

Population: Participants who responded to the measures at the time point of interest, day 8

The average score on beliefs about LCC harms measured with 10 items by survey, are an average of the responses to the 10 questions. Belief scoring is on a scale of 1 to 5, where 1 indicates strong disagreement with statements about the health harms of LCCs and 5 indicates strong agreement with the statements about the health harms of LCCs.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=256 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=236 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=249 Participants
Participants will receive FDA-proposed LCC warnings with images.
Beliefs About Little Cigar and Cigarillo (LCC) Harms
4.31 score on a scale
Standard Deviation 0.54
4.24 score on a scale
Standard Deviation 0.59
4.30 score on a scale
Standard Deviation 0.58

SECONDARY outcome

Timeframe: Day 3

Population: Participants who responded to the scale at the time point of interest, day 3

The cognitive elaboration score is measured by survey with 1 item. Question scoring is on a scale of 1 to 6, where 1 indicates that the participant has low cognitive elaboration about the health risks of LCCs and 6 indicates that a participant has high cognitive elaboration about smoking LCCs.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=240 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=227 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=231 Participants
Participants will receive FDA-proposed LCC warnings with images.
Cognitive Elaboration About Risk of Little Cigar and Cigarillo Use
4.08 units on a scale
Standard Deviation 1.50
3.74 units on a scale
Standard Deviation 1.64
3.97 units on a scale
Standard Deviation 1.46

SECONDARY outcome

Timeframe: Day 4

Population: Participants who responded to the scale at the time point of interest, day 4

The cognitive elaboration score is measured by survey with 1 item. Question scoring is on a scale of 1 to 6, where 1 indicates that the participant has low cognitive elaboration about the health risks of LCCs and 6 indicates that a participant has high cognitive elaboration about smoking LCCs.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=233 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=216 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=238 Participants
Participants will receive FDA-proposed LCC warnings with images.
Cognitive Elaboration About Risk of Little Cigar and Cigarillo Use
3.94 units on a scale
Standard Deviation 1.52
3.74 units on a scale
Standard Deviation 1.65
3.88 units on a scale
Standard Deviation 1.59

SECONDARY outcome

Timeframe: Day 5

Population: Participants who responded to the scale at the time point of interest, day 5

The cognitive elaboration score is measured by survey with 1 item. Question scoring is on a scale of 1 to 6, where 1 indicates that the participant has low cognitive elaboration about the health risks of LCCs and 6 indicates that a participant has high cognitive elaboration about smoking LCCs.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=238 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=217 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=225 Participants
Participants will receive FDA-proposed LCC warnings with images.
Cognitive Elaboration About Risk of Little Cigar and Cigarillo Use
4.08 units on a scale
Standard Deviation 1.54
3.88 units on a scale
Standard Deviation 1.64
4.00 units on a scale
Standard Deviation 1.53

SECONDARY outcome

Timeframe: Day 6

Population: Participants who responded to the scale at the time point of interest, day 6

The cognitive elaboration score is measured by survey with 1 item. Question scoring is on a scale of 1 to 6, where 1 indicates that the participant has low cognitive elaboration about the health risks of LCCs and 6 indicates that a participant has high cognitive elaboration about smoking LCCs.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=222 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=217 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=230 Participants
Participants will receive FDA-proposed LCC warnings with images.
Cognitive Elaboration About Risk of Little Cigar and Cigarillo Use
4.05 units on a scale
Standard Deviation 1.59
3.78 units on a scale
Standard Deviation 1.67
4.01 units on a scale
Standard Deviation 1.58

SECONDARY outcome

Timeframe: Day 7

Population: Participants who responded to the scale at the time point of interest, day 7

The cognitive elaboration score is measured by survey with 1 item. Question scoring is on a scale of 1 to 6, where 1 indicates that the participant has low cognitive elaboration about the health risks of LCCs and 6 indicates that a participant has high cognitive elaboration about smoking LCCs.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=208 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=209 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=218 Participants
Participants will receive FDA-proposed LCC warnings with images.
Cognitive Elaboration About Risk of Little Cigar and Cigarillo Use
4.11 units on a scale
Standard Deviation 1.50
3.83 units on a scale
Standard Deviation 1.70
3.98 units on a scale
Standard Deviation 1.54

SECONDARY outcome

Timeframe: Day 8

Population: Participants who responded to the scale at the time point of interest, day 8

The cognitive elaboration score is measured by survey with 1 item. Question scoring is on a scale of 1 to 6, where 1 indicates that the participant has low cognitive elaboration about the health risks of LCCs and 6 indicates that a participant has high cognitive elaboration about smoking LCCs.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=256 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=236 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=250 Participants
Participants will receive FDA-proposed LCC warnings with images.
Cognitive Elaboration About Risk of Little Cigar and Cigarillo Use
3.99 units on a scale
Standard Deviation 1.52
4.00 units on a scale
Standard Deviation 1.60
4.12 units on a scale
Standard Deviation 1.55

SECONDARY outcome

Timeframe: Day 3

Population: Participants who responded to the scale at the time point of interest, day 3

Warning negative affect/worry is measured by survey with 1 item. Question scoring is on a scale of 1 to 5, where 1 indicates low worry due to the warning and 5 indicates high worry due to the warning.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=240 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=227 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=231 Participants
Participants will receive FDA-proposed LCC warnings with images.
Warning Negative Affect/Worry
3.42 units on a scale
Standard Deviation 1.24
3.48 units on a scale
Standard Deviation 1.26
4.02 units on a scale
Standard Deviation 1.04

SECONDARY outcome

Timeframe: Day 4

Population: Participants who responded to the scale at the time point of interest, day 4

Warning negative affect/worry is measured by survey with 1 item. Question scoring is on a scale of 1 to 5, where 1 indicates low worry due to the warning and 5 indicates high worry due to the warning.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=233 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=216 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=238 Participants
Participants will receive FDA-proposed LCC warnings with images.
Warning Negative Affect/Worry
3.55 units on a scale
Standard Deviation 1.25
3.65 units on a scale
Standard Deviation 1.20
4.03 units on a scale
Standard Deviation 1.15

SECONDARY outcome

Timeframe: Day 5

Population: Participants who responded to the scale at the time point of interest, day 5

Warning negative affect/worry is measured by survey with 1 item. Question scoring is on a scale of 1 to 5, where 1 indicates low worry due to the warning and 5 indicates high worry due to the warning.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=238 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=217 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=225 Participants
Participants will receive FDA-proposed LCC warnings with images.
Warning Negative Affect/Worry
3.52 units on a scale
Standard Deviation 1.38
3.36 units on a scale
Standard Deviation 1.29
4.00 units on a scale
Standard Deviation 1.13

SECONDARY outcome

Timeframe: Day 6

Population: Participants who responded to the scale at the time point of interest, day 6

Warning negative affect/worry is measured by survey with 1 item. Question scoring is on a scale of 1 to 5, where 1 indicates low worry due to the warning and 5 indicates high worry due to the warning.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=222 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=217 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=230 Participants
Participants will receive FDA-proposed LCC warnings with images.
Warning Negative Affect/Worry
3.72 units on a scale
Standard Deviation 1.23
3.71 units on a scale
Standard Deviation 1.23
4.02 units on a scale
Standard Deviation 1.08

SECONDARY outcome

Timeframe: Day 7

Population: Participants who responded to the scale at the time point of interest, day 7

Warning negative affect/worry is measured by survey with 1 item. Question scoring is on a scale of 1 to 5, where 1 indicates low worry due to the warning and 5 indicates high worry due to the warning.

Outcome measures

Outcome measures
Measure
FDA Warnings Text-Only Warnings
n=208 Participants
Participants will receive FDA-proposed text-only LCC warnings.
Surgeon General Text-Only Warnings
n=209 Participants
Participants will receive Surgeon General text-only LCC warnings.
FDA Warnings + Image
n=218 Participants
Participants will receive FDA-proposed LCC warnings with images.
Warning Negative Affect/Worry
3.79 units on a scale
Standard Deviation 1.15
3.79 units on a scale
Standard Deviation 1.16
3.90 units on a scale
Standard Deviation 1.13

Adverse Events

Surgeon General Text-Only Warnings

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

FDA Warnings + Image

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

FDA Warnings Text-Only Warnings

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Leah Ranney, PhD, MA, Research Professor and Director of the Tobacco Prevention and Evaluation Progr

University of North Carolina at Chapel Hill, School of Medicine, Department of Family Medicine, and Lineberger Comprehensive Cancer Center

Phone: 984-974-4888

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place